TRIAL SNAPSHOT

Acronym: EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

PHASE:
2
NCT#:
NCT00000000
STATUS:
Not yet recruiting
START DATE:
00/00/0000
LOCATION:
United States, New York, NY
END DATE:
00/00/0000
GENERIC DRUG NAME:
Drug Name Here

Investigators

TRIAL ARTICLES

Impact of PORT on Outcomes in Advanced TESCC

by Oncweekly Editor | Sep 30, 2024 | Esophageal Cancer, Gastrointestinal Cancer

KEY TAKEAWAYS The study aimed to investigate the long-term outcomes of locally advanced TESCC with and without postoperative radiotherapy. Researchers noticed that postoperative radiotherapy improves survival and reduces recurrence in patients with advanced T3-4 TESCC...

BTN3A1 Drives Vγ9Vδ2 T Cell Exhaustion in Cervical Cancer

by Oncweekly Editor | Sep 30, 2024 | Cervical Cancer, Gynecologic Cancer

KEY TAKEAWAYS The study aimed to explore how BTN3A1 promotes Vγ9Vδ2 T cell exhaustion by upregulating NR4A2/3. The results showed BTN3A1 promotes T cell exhaustion by inducing NR4A2/3 in cervical cancer. Jian Liu and the team aimed to investigate how BTN3A1 in...